Full Year '24 Results: Amgen Lobby Spending; Year Over Year Trends, Against Three Other Majors...

We have covered both Merck and Pfizer, in the Q4 '24 lobby spends, of each -- do see below, yesterday. Now it is time to look at the run-away full year 2024 leader: Amgen. This year's spending was truly outsized -- for the Thousand Oaks company -- and doubly so -- for an election year.

In any event, here is the (very hefty!) list of what all the bioscience major, Amgen spent on -- just looking at Q4 '24. But as I've said, I would expect Pfizer to once again be the overall spend leader in the full year 2025 -- if for no other reason than that it is about double the size of most of the others, on market cap and global revenue:

. . .▲ Issues related to drug pricing reform; Changes to Public law 117-1769 Inflation Reduction Act; Awareness of implications to patients and research and development of Public law 117-1769; Inflation Reduction Act; S. 113 Prescription Pricing for the People Act of 2023; S.127 Pharmacy Benefit Manager Transparency Act; HR 830/ S 1375 HELP Copays Act; HR 485 Protecting Health Care for All Patients Act; HR 5378 Lower Costs, More Transparency Act; R 2534 PROTECT 340B Act of 2023; HR 3561 the PATIENT Act; S. 1542 DRUG Act; S. 1967 PBM Act; HR 3503 The NIH Clinical Trials Diversity Act; Issues related to cardiovascular disease awareness and treatment; Issues related to Federal Trade Commission; FDA issues; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Biosimilars reimbursement issues, no specific bill; Supply Chain Issues, no specific bill; Issues related to 340B; Issues related to pharmacy benefit managers; Proposed rule: Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program; HR 4818/ S. 2407 Treat and Reduce Obesity Act; S. 2305 Biosimilar Red Tape Elimination Act; S. 2129 Ensuring Access to Lower-Cost Medicines for Seniors Act; Issues related to PAHPA reauthorization; Modernizing and Ensuring PBM Accountability Act (Finance Committee); S. 652/ HR2630 SAFE Step Act; S 2474/ HR 5376 Share the Savings with Seniors Act; S 2456 Protecting Seniors from High Drug Costs Act; HR4881 To amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program; HR 3281 Protecting Patients Against PBM Abuses Act; HR 4822 Health Care Price Transparency Act of 2023; S 1339 Pharmacy Benefit Manager Reform Act; HR 2679 Pharmacy Benefits Manager Accountability Act; HR 4507 Transparency in Coverage Act of 2023; HR 1352 Increasing Access to Biosimilars Act of 2023; HR 2880 Protecting Patients Against PBM Abuses Act; Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions; HR 5539 Orphan Cures Act; HR 5547 Maintaining Investments in New Innovation Act; S 3558 BIOSECURE Act; HR 7174 Ensuring Pathways to Innovative Cures (EPIC Act); S Res 566 Cholesterol Education Month 2024; HR 7635 340B PATIENTS Act of 2024; H.R. 5391 / S. 2764 The Protecting Patient Access to Cancer and Complex Therapies Act; H.R.8574 - 340B Affording Care for Communities and Ensuring a Strong Safety-net Act; HR 5376 Share the Savings With Seniors Act; S 3430 Mental Health, Lower Cost Drugs and Extenders Package; BIOCOMPETE (no bill number)- Issues related to prohibiting the export of biotechnology to certain foreign entities; HR 8412 Clinical Trial Modernization Act; S 5573 Skinny Labels, Big Savings Act; HR 10515 American Relief Act. . . .

▲ Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income; HR 3938 Build it in America Act. . . .

▲ S. 79/HR 1717 Interagency Patent Coordination and Improvement Act of 2023; S. 113 Prescription Pricing for the People Act of 2023; S. 1250 Drug-price Transparency for Consumers Act; S.127 Pharmacy Benefit Transparency Act; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop STALLING Act; S. 142 Preserve Access to Affordable Generics and Biosimilars; Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to patent thickets/product hopping; Issues related to obviousness/double patenting; S.2140 Patent Eligibility Restoration Act of 2023; S.2220/HR 4370 Promoting and Respecting Economically Vital American Innovation Leadership Act; S.1128: A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents; H.R. 3858/S.1834: A bill to prohibit the

President from negotiating or concluding any withdrawal, suspension, waiver, or modification to the Agreement on Trade-Related Aspects of Intellectual Property Rights without explicit authorization from Congress; H.R. 3535 Advancing Americas Interests Act; H.R. 5475 Prohibiting Adversarial Patents Act of 2023; S.3385/HR 8333-- BIOSECURE Act; BIOCOMPETE (no bill number) -- Issues related to prohibiting the export of biotechnology to certain foreign entities; Issues related to FDA/PTO coordination; S.2780 Medication Affordability and Patent Integrity Act; Issues related to skinny labeling; S. 3583/HR 6986 To Address Patent Thickets; S. 1956 Invent It Here, Make It Here Act; S 5573 Skinny Labels, Big Savings Act [Ed. Note: Seriously?!]. . . .

Now you know -- and depending on other commitments, we may not separately cover Lilly this quarter, since it only spent $190,000 all in. Indeed, starting next week, postings may diminish overall here -- as I spend more of my free daylight hours, in pro bono / street law / ACLU-directed and filed-federal litigation practice, against the largely comically inept Tangerine 2.0 "initiatives". Onward, resolutely. Ever, onward.

नमस्ते